[First new oral anticoagulant with specific antidote].
作者信息
Einecke Dirk
机构信息
.
出版信息
MMW Fortschr Med. 2016 Mar 17;158(5):73. doi: 10.1007/s15006-016-7952-3.
PMID:26979233
Abstract
摘要
相似文献
1
[First new oral anticoagulant with specific antidote].[首款具有特异性解毒剂的新型口服抗凝药]
MMW Fortschr Med. 2016 Mar 17;158(5):73. doi: 10.1007/s15006-016-7952-3.
2
[First NOAk specific antidote as additional safety factor in therapy].[首个诺阿克特异性解毒剂作为治疗中的额外安全因素]
MMW Fortschr Med. 2016 Feb 4;158(2):66-7.
3
[Anticoagulant activity is rapidly reversed].抗凝活性迅速逆转。
MMW Fortschr Med. 2016 Feb 4;158(2):67.
4
Security profile of direct anticoagulants. Preferred use in atrial fibrillation.直接凝血酶抑制剂的安全性概况。在心房颤动中的首选应用。
Clin Investig Arterioscler. 2019 Nov-Dec;31(6):263-270. doi: 10.1016/j.arteri.2019.03.002. Epub 2019 Jun 15.
5
[First NOAK with specific antidote].
MMW Fortschr Med. 2015 Dec 14;157(21-22):84. doi: 10.1007/s15006-015-7626-6.
6
The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran.解毒剂终于来了！艾达司珠单抗，一种用于达比加群抗凝作用的特异性逆转剂。
Clin Nurse Spec. 2016 Mar-Apr;30(2):81-3; quiz E9. doi: 10.1097/NUR.0000000000000192.
7
[First NOAK antidote soon to be approved].首款诺阿克解毒剂即将获批。
MMW Fortschr Med. 2015 Aug 20;157(14):34. doi: 10.1007/s15006-015-3409-3.
8
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.达比加群相关出血的逆转药物idarucizumab：当前证据回顾。
J Thromb Thrombolysis. 2017 Nov;44(4):527-535. doi: 10.1007/s11239-017-1555-4.
9
Idarucizumab: The Antidote for Reversal of Dabigatran.艾达司珠单抗：达比加群逆转的解毒剂。
Circulation. 2015 Dec 22;132(25):2412-22. doi: 10.1161/CIRCULATIONAHA.115.019628.
10
[Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke].[急性缺血性卒中患者接受艾达司珠单抗治疗后进行全身溶栓]
Ideggyogy Sz. 2017 Jul 30;70(7-8):284-288. doi: 10.18071/isz.70.0284.
Zotero 插件